ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
AZ/Daiichi Sankyo's Enhertu picks up third breakthrough designation
May 19, 2020AstraZeneca's and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation (BTD) in the US for the treatment of patients with a particular form of lung cancer. -
US nod for Lynparza in HRD-positive advanced ovarian cancer
May 12, 2020AstraZeneca and MSD's Lynparza (olaparib) has been cleared in the US for use as a first-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer. -
FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies
December 23, 2019The U.S. Food and Drug Administration granted accelerated approval to Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of adults with unresectable ...
Pharma Sources Insight January 2025
